Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SVRA vs DSGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SVRA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)

SVRA Overall Winner 6-Pillar Tally: SVRA 3 – 2 DSGN (1 Tie) Matrix Metrics: SVRA 4 – 3 DSGN

As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SVRA carries a Unified Composite Score of 55.6/100 (HOLD) at $4.42 (0.4x Forward P/E, 0.0% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.6); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SVRA vs DSGN
SVRA NASDAQ Head-to-Head Winner
Savara Inc.
Pharmaceutical Preparations
$4.42
-4.63% 1D
Market Cap $1.1B
TTM Revenue $1,000
Forward P/E 0.4x
Beta / 30D Vol 1.48β · 73% Vol
Unified Composite Score
55.6 / 100 HOLD
Tech 30.0 Fund 54.0 Flow 70.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.8%), weak momentum, RSI 42
RSI-14: 41.6 · SMA20: $4.72 · SMA50: $4.92
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 55.0 Fund 57.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $10.53 · SMA50: $11.58

6-Pillar Scorecard Institutional Category Breakdown (SVRA 3 – 2 DSGN)

Columns: Metric · SVRA · DSGN
1. Valuation Multiples SVRA
Forward P/E 0.4x N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SVRA
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $33,000
Market Cap $1.1B $677.5M
3. Profitability & Quality DSGN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -151.0% -36.9%
4. Balance Sheet & Cash Flow DSGN
Cash Generation (TTM) -$131M -$59M
Cash Flow Margin N/A N/A
Net Cash / Leverage $551,000 Net Debt (0.28x D/E) $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SVRA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 164.3% (17th %ile) 92.0% (13th %ile)
Put/Call OI Skew 0.05x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SVRA (4) vs DSGN (3)
Institutional Metric SVRA DSGN Criterion Row Edge
Market Capitalization
Scale
$1.1B $677.5M Larger Scale SVRA
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple SVRA
Forward P/E Ratio
Valuation
0.4x N/M Lower Multiple SVRA
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-151.0% -36.9% Higher ROE DSGN
52-Week Range Position
Momentum
13% ($4–$7) 30% ($7–$17) Stronger Trend DSGN
Beta / 30D Volatility
Risk Regime
1.48β · 73% Vol 1.32β · 61% Vol Lower Realized Risk DSGN
Unified Institutional Score
Composite Signal
55.6 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite SVRA
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $33,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$131M ($551,000 Net Debt (0.28x D/E)) -$59M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SVRA +3.03 pp
SVRA: -0.56% · DSGN: -3.59%
3M Horizon SVRA +17.31 pp
SVRA: -17.6% · DSGN: -34.91%
6M Horizon DSGN +2.78 pp
SVRA: -9.88% · DSGN: -7.1%
1Y Horizon DSGN +36.92 pp
SVRA: +3.87% · DSGN: +40.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SVRA Revenue DSGN Revenue SVRA Op. Margin DSGN Op. Margin Margin Leader
FY2010 $0M N/A -1746.5% N/A SVRA
FY2015 $0M N/A -10968.5% N/A SVRA
FY2016 $0M N/A -2737.0% N/A SVRA
FY2020 $0M $0M -19182.9% -3685.8% DSGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SVRA BREAKDOWN
92d in phase · OBV ACCUMULATION
Current IV 164.3%
IV Percentile 17th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SVRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SVRA vs DSGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SVRA carries a Unified Composite Score of 55.6/100 (HOLD) at $4.42 (0.4x Forward P/E, 0.0% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.6); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SVRA leads the Growth & Scale pillar: SVRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 4-period historical trajectory (FY2010 to FY2020), SVRA cumulative revenue shifted N/A while DSGN shifted N/A. In operating R&D and SG&A reinvestment, SVRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.

SVRA screens cheaper on headline valuation multiples. SVRA trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SVRA (-151.0% ROE) versus DSGN (-36.9% ROE) capital efficiency.

In options market volatility and institutional positioning, SVRA carries 164.3% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 73% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.